$38m jump-start for MyoKardia as it pursues cardiomyopathy niche
This article was originally published in Scrip
US startup MyoKardia has raised $38 million from a Series A financing without a compound singled out as a lead drug candidate, but by leveraging the expertise of its scientific founders the San Francisco-based company is targeting the eight genes connected to hundreds of genetic mutations that cause hypertrophic and dilated cardiomyopathies.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.